New drugs for ALS: How do we get there?
Author:
- Jonathan D. GlassJGJonathan D. Glass
- 1 January 2012
- journal article
- Published by Elsevier in Experimental Neurology
- Vol. 233 (1) , 112-117
Abstract
No abstract availableThis publication has 71 references indexed in Scilit:
- Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based studyJournal of Neurology, Neurosurgery & Psychiatry, 2011
- New Strategies in HER2-Overexpressing Breast Cancer: Many Combinations of Targeted Drugs AvailableClinical Cancer Research, 2011
- Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF‐H) in blood of ALS model rodents and ALS patients: evaluation of blood pNF‐H as a potential ALS biomarkerJournal of Neurochemistry, 2009
- Multiple roles of HDAC inhibition in neurodegenerative conditionsTrends in Neurosciences, 2009
- The Phosphorylated Axonal Form of the Neurofilament Subunit NF-H (pNF-H) as a Blood Biomarker of Traumatic Brain InjuryJournal of Neurotrauma, 2008
- Biomarkers for amyotrophic lateral sclerosisExpert Review of Molecular Diagnostics, 2006
- In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproateAnnals of Neurology, 2006
- Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophyEuropean Journal of Human Genetics, 2003
- Neurologists strike gold in drug screen effortNature, 2002
- A controlled trial of recombinant methionyl human BDNF in ALSNeurology, 1999